Medscape Conference Coverage, based on selected sessions at the:

EuroPCR 2008: European Paris Course on Revascularization

May 13 - 16, 2008; Barcelona, Spain

This activity is not sanctioned by, nor a part of, the European Association for Percutaneous Cardiovascular Interventions. Conference news does not receive grant support and is produced independently.

Conference News

  • CACTUS: One or Two Stents Fine for Bifurcations

    The trial, comparing the crush technique with provisional T-stenting in bifurcation lesions, suggests that outcomes are similar, regardless of the technique used, at least in "true" bifurcation lesions where both the main vessel and side branch have significant stenosis.
    Heartwire, May 28, 2008
  • CUSTOM III: New Data for the Customizable DES

    Lengths A multicenter registry study using the Custom NX DES has again shown that the device is safe in long lesions and in a smaller group of patients receiving two stents delivered consecutively from a single 60-mm section. Randomized controlled trials are the next step, investigators say.
    Heartwire, May 23, 2008
  • First "Healing" Stent Data Show Promise

    Results from the ongoing multicenter TRIAS-HR/LR trials will be needed to determine whether the Genous endothelial-cell-capture stent becomes a niche product for people who can't take clopidogrel or who face a high thrombosis risk or if it will compete with DES.
    Heartwire, May 16, 2008
  • Delipidated HDL for Plaque Regression?

    Very preliminary data from a pilot study indicates that stripping a patient's own HDL of its lipid content, then reinfusing it, is feasible and safe and may even offer a novel means of stabilizing atherosclerotic plaques.
    Heartwire, May 16, 2008
  • Stent-Thrombosis Rates Higher for Taxus

    The latest data from the Western Denmark registry, broken down by stent type, suggests that Taxus-treated patients face a nearly fivefold higher risk of stent thrombosis and a 50% higher risk of death between 12 and 24 months; no such increases were seen in Cypher-treated patients.
    Heartwire, May 15, 2008
  • Can IVUS Improve Clinical Outcomes?

    Proponents say intravascular ultrasound can reduce stent underexpansion and improve placement--things that should translate into less stent thrombosis/restenosis. But in the absence of large randomized clinical trials, others argue the technology is too expensive, prolongs procedures, and requires too much expertise to use on a routine basis.
    Heartwire, May 14, 2008
  • Xience and Nobori Stents: Promising 2-Year Data

    Enduring clinical results suggest that the newer platforms, with limus-type drugs, may offer an edge over the first DES on the market.
    Heartwire, May 14, 2008

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the European Association for Percutaneous Cardiovascular Interventions. These materials and the related activity are not sanctioned by the European Association for Percutaneous Cardiovascular Interventions or the commercial supporter of the conference and do not constitute an official part of that conference.